

This article was downloaded by:[University of Pittsburgh]
On: 2 August 2007
Access Details: [subscription number 769430029]
Publisher: Informa Healthcare
Informa Ltd Registered in England and Wales Registered Number: 1072954
Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Hemoglobin

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597254>

Hb Alesha [β 67(E11)VaMet, **GTATG**] in an Argentinean Girl

Online Publication Date: 01 July 2007

To cite this Article: Eberle, Silvia Eandi, Noguera, Nélide I., Sciuccati, Gabriela, Bonduel, Mariana, Díaz, Lilian, Staciuk, Raquel, Targovnik, Héctor M. and Feliu-Torres, Aurora (2007) 'Hb Alesha [β 67(E11)VaMet, **GTATG**] in an Argentinean Girl', Hemoglobin, 31:3, 379 - 382

To link to this article: DOI: 10.1080/03630260701459408

URL: <http://dx.doi.org/10.1080/03630260701459408>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article maybe used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

© Taylor and Francis 2007

SHORT COMMUNICATION

Hb ALESHA [$\beta 67(\text{E11})\text{Val}\rightarrow\text{Met}$, $\text{GTG}\rightarrow\text{ATG}$] IN AN ARGENTINEAN GIRL

Silvia Eandi Eberle,¹ Nélide I. Noguera,² Gabriela Sciuccati,¹ Mariana Bonduel,¹ Lilian Díaz,¹ Raquel Staciuk,¹ Héctor M. Targovnik,³ and Aurora Feliu-Torres¹

¹*Servicio de Hematología-Oncología, Hospital de Pediatría “Prof. Dr. Juan. P. Garrahan,” Buenos Aires, Argentina*

²*Departamento de Bioquímica Clínica, Área de Hematología, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Santa Fe, Argentina*

³*Laboratorio de Biología Molecular, Cátedra de Genética y Biología Molecular, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina*

□ *Hb Alesha is caused by a $\text{GTG}\rightarrow\text{ATG}$ mutation at codon 67 of the β -globin gene, resulting in abnormal β -globin chains in which the normal $\beta 67(\text{E11})$ valine is changed to methionine. This hemoglobin (Hb) is also known as Hb Bristol, the first unstable Hb described, since in a fraction of the variant the methionine is modified into an aspartic acid by a posttranslational modification. This replacement disrupts the apolar bonds between the valine and the heme group, producing an unstable Hb and severe hemolysis. We have identified this rare hemoglobinopathy in an Argentinean girl with severe hemolytic anemia, splenomegaly and frequent requirement for red blood cell transfusions.*

Keywords Unstable hemoglobin (Hb), Abnormal Hb, Hemolytic anemia

The structural hemoglobin (Hb) variants mostly result from single amino acid substitutions in the α or β chains. In many cases, these are innocuous but in others they may alter the stability or functional properties of the Hb and lead to clinical disorder (1). Unstable Hb Alesha [$\beta 67(\text{E11})\text{Val}\rightarrow\text{Met}$, $\text{GTG}\rightarrow\text{ATG}$] was reported by Molchanova

Received 27 November 2006; accepted 30 January 2007.

Address correspondence to Dr. Aurora Feliu-Torres, Servicio de Hematología-Oncología, Hospital de Pediatría “Prof. Dr. J. P. Garrahan,” Combate de los Pozos 1881, (C1245AAM) Buenos Aires, Argentina; Tel.: +54-11-4308-4300, Ext: 1301-1597; Fax: +54-11-4308-5325; E-mail: afeliutorres@yahoo.com; afeliu@garrahan.gov.ar

et al. (2), and in a patient with a Moyamoya syndrome by Brockmann *et al.* (3).

In 1952, the first unstable Hb was found, and its structural study showed that the valine at $\beta 67$ was replaced by an aspartic acid, and this variant was named Hb Bristol. In 1996, Rees *et al.* (4) restudied these patients, previously diagnosed as carriers of Hb Bristol, finding the GTG \rightarrow ATG mutation at codon 67 in the β -globin gene, predicting a valine to methionine substitution similar to Hb Alesha. Further analysis with electrospray ionization mass spectrometry (ESI-MS) and globin change biosynthesis, suggested that this anomaly is due to a novel posttranslational mechanism with conversion of the translated methionine into an aspartate residue.

We recently detected a hemoglobinopathy in a 4-year-old girl with severe hemolytic anemia, splenomegaly and frequent requirements for red blood cell transfusions. The patient was born at term, after a normal pregnancy, by Cesarean section. During the neonatal period, she developed hyperbilirubinemia requiring phototherapy. Rhesus and ABO isoimmune hemolysis were ruled out. Urine culture was positive for *E. coli* and parenteral antibiotics were given. She had a history of multiple episodes of pallor and jaundice related to infections and has received several red blood cell transfusions since the age of 6 months. A splenectomy was performed 3 years later in an attempt to reduce the transfusion requirements. On admission to our Institution her physical examination revealed growth delay, peculiar facial appearance with bossing of the skull, hypertrophy of the maxilla, prominent malar eminences and mongoloid slant of the eyes, generalized icterus, pallor and marked hepatosplenomegaly.

Hematological parameters were measured with a Coulter Counter Model JT (Coulter Corporation, Hialeah, FL, USA). Hemolysates were analyzed by electrophoresis on cellulose acetate at pH 8.4 and on agar citrate at pH 6.0 (5). Hb A₂ was measured by anion exchange chromatography (6) and Hb F according to the method described by Betke *et al.* (7). Reticulocytes, Heinz body formation, heat denaturation and isopropanol instability tests were performed using standard methods (5). Venous blood samples, under anaerobic conditions, were collected with heparin as anticoagulant for the P₅₀ determination. Measurements were performed on the Radiometer ABL 520 analyzer (Radiometer A/S, Copenhagen, Denmark). Actual P₅₀ was calculated by the simplified oxygen status algorithm studies (8–10). DNA was extracted from peripheral blood samples by standard methods after previous written informed consent. The coding regions of the β -globin gene were amplified in two segments, and polymerase chain reaction (PCR) amplification was accomplished according to conditions already described (11).

The patient showed the following hematological data: Hb 8.4 g/dL, RBC $2.16 \times 10^{12}/L$, PCV 0.28 L/L, MCV 128.9 fL, MCH 30.8 pg, MCHC

34.0 g/dL and reticulocytes 25%. The peripheral blood smear showed severe anisocytosis with macrocytosis, pronounced basophilic stippling and polychromatophilia. Blood chemistry showed: unconjugated bilirubin 544 $\mu\text{mol/L}$ (normal range 51–170 $\mu\text{mol/L}$); total bilirubin 969 $\mu\text{mol/L}$ (normal range 68–238 $\mu\text{mol/L}$); haptoglobin <5 mg/dL (normal range 70–378 mg/dL); LDH 1951 UI/L (normal range 137–415 UI/L). Both instability tests were positive and Heinz bodies were present in the red cells after incubation with brilliant cresyl blue. Hb A₂ was 2.9% and Hb F 5.6%. The oxygen dissociation curve (ODC) showed a shift to the right (P_{50} 33.62 mm Hg, normal value: 27 ± 2 mm Hg).

Electrophoretic cellulose acetate and citrate agar were normal, however, sequencing of the β -globin gene showed a substitution of GTG→ATG at codon 67, corresponding to Hb Alesha. This Hb is characterized by a substitution of valine to methionine at position 67(E11) of the β chain. The introduction of the larger methionine residue into the heme pocket, and the loss of the bonds between valine at $\beta 67$ and the heme group, adequately account for the severe instability of Hb Alesha and the clinical condition found in this patient. Hb Alesha is electrophoretically silent with standard procedures, although partial separation of Hb X and Hb A by cation exchange high performance liquid chromatography (HPLC) has been reported (12,13).

It is important to emphasize the results found by Rees *et al.* (4) when they restudied the patients with Hb Bristol. Their findings, using DNA and protein analyses, show that the original characterization of Hb Bristol was partly incorrect, in that a silent posttranslational modification of Met→Asp was mistaken for the primary mutation, which is in fact $\beta 67(\text{E11})\text{Val}\rightarrow\text{Met}$. According to these studies, both Hbs (Hb Alesha and Hb Bristol) are the same entity. In our patient, this unstable Hb is very likely a *de novo* mutation, since both parents proved to be normal.

ACKNOWLEDGMENTS

This study was supported by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Hospital de Pediatría Prof. Dr. J. P. Garrahan and Facultad de Bioquímica y Farmacia, Universidad Nacional de Rosario, Santa Fe, Argentina.

REFERENCES

1. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin. Genetics, Pathophysiology, and Clinical Management. Cambridge: Cambridge University Press, 2001.
2. Molchanova TP, Postnikov YuV, Pobedinskaya DD, Smetanina NS, Moschan AA, Kazanetz EG, Tokarev YuN, Huisman THJ. Hb Alesha or $\alpha_2\beta_2 67(\text{E11})\text{Val}\rightarrow\text{Met}$: a new unstable hemoglobin variant identified through sequencing of amplified DNA. Hemoglobin 1993; 17(3):217–225.

3. Brockmann K, Stolpe S, Fels C, Kahn N, Kulozik AE, Pekrun A. Moyamoya Syndrome associated with hemolytic anemia due to Hb Alesha. *J Pediatr Hematol Oncol* 2005; 27(8):436–440.
4. Rees DC, Rochette J, Schofield C, Green B, Morris M, Parker NE, Sasaki H, Tanaka A, Ohba Y, Clegg JB. A novel silent posttranslational mechanism converts methionine to aspartate in Hemoglobin Bristol ($\beta 67[\text{E11}]\text{Val-Met}\rightarrow\text{Asp}$). *Blood* 1996; 88(1):341–348.
5. Dacie JV, Lewis SM. *Practical Haematology*, 9th ed. London: Churchill Livingstone, 2001.
6. International Committee for Standardization in Hematology: recommendations for select methods for quantitative estimation of Hb A₂ and for Hb A₂ reference preparation. *Br J Haematol* 1978; 38(4):573–578.
7. Betke K, Marti HR, Schlicht I. Estimation of small percentages of foetal haemoglobin. *Nature* 1959; 184(Suppl 24):1877–1878.
8. Siggaard-Andersen O, Wimberley PD, Gothgen IH, Siggaard-Andersen M. A mathematical model of the hemoglobin-oxygen dissociation curve of human blood and of the oxygen partial pressure as a function of temperature. *Clin Chem* 1984; 30(10):1646–1651.
9. Siggaard-Andersen O, Wimberley PD, Gothgen IH, Fogh-Andersen N. Measured and derived quantities with modern pH and blood gas equipment: calculation algorithms with 54 equations. *Scand J Clin Invest* 1988; 48(Suppl 189):7–15.
10. Siggaard-Andersen O, Siggaard-Andersen M. The oxygen status algorithm: a computer program for calculating and displaying pH and blood gas data. *Scand J Clin Lab Invest* 1990; 50(Suppl 203):29–45.
11. Noguera NI, Cardozo MA, Gonzalez FA, Benavente C, Milani AC, Villegas A. Hb Agenogi [$\beta 90(\text{F6})\text{Glu}\rightarrow\text{Lys}$] in an Argentinean girl. *Hemoglobin* 2002; 26(2):201–203.
12. Hardison RC, Chui DHK, Riemer CR, Miller W, Carver MFH, Molchanova TP, Efremov GD, Huisman THJ. Access to *A Syllabus of Human Hemoglobin Variants (1996)* via the world wide web. *Hemoglobin* 1998; 22(2):113–127 (<http://globin.cse.psu.edu>).
13. Huisman THJ, Carver MFH, Efremov GD. *A Syllabus of Human Hemoglobin Variants (Second Edition)*. Augusta: The Sickle Cell Anemia Foundation, 1998 (<http://globin.cse.psu.edu>).